nach oben

2015 | OriginalPaper | Buchkapitel

38. Pankreastumoren

Autoren: Prof. Dr. med. Marcus Bahra, Prof. Dr. med. Florian Lordick, Professor Dr. med. Manfred P. Lutz, Prof. Dr. med. Matthias Glanemann, Prof. Dr. med. Peter Neuhaus

Verlag: Springer Berlin Heidelberg

Erschienen in: Viszeralmedizin

» Jetzt Zugang zum Volltext erhalten

Zusammenfassung

Autoren

Gastroenterologie: M. P. Lutz

Onkologie: F. Lordick

Viszeralchirurgie: M. Bahra, M. Glanemann, P. Neuhaus

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

b.Flat Gastrointestinale Chirurgie

Das Paket für alle Viszeral- und Allgemeinchirurgen, die ihren Schwerpunkt in der gastrointestinalen Chirurgie haben und sich für die ganze Breite des Bereichs interessieren. Das Abo beinhaltet:

Onlinezugriff auf die Inhalte von 9 Springer Chirurgie-Fachbüchern
Immer die neueste Auflagen
Volltextsuche, Lesezeichen und offline lesen

Jetzt informieren

b.Flat Viszeral- und Allgemeinchirurgie 360°

Das umfangreiche Paket für alle Viszeral- und Allgemeinchirurgen, die sich für die ganze Breite der beiden Fachgebiete und auch für Spezialthemen interessieren. Das Abo beinhaltet:

Onlinezugriff auf die Inhalte von 16 Springer Chirurgie-Fachbüchern
Immer die neueste Auflagen
Volltextsuche, Lesezeichen und offline lesen

Jetzt informieren

Adamek HE et al (2000) Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study. Lancet 356(9225):190–193 CrossRefPubMed

Alexakis N, Halloran C et al (2004) Current standards of surgery for pancreatic cancer. Br J Surg 91(11):1410–1427 CrossRefPubMed

Aristu J et al (2003) Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer. Am J Clin Oncol 26(1):30–36 CrossRefPubMed

Azria D et al (2002) Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cisplatin. Pancreas 25(4):360–365 CrossRefPubMed

Bajetta E et al (1999) Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study. Int J Radiat Oncol Biol Phys 45(2):285–289 CrossRefPubMed

Bartsch DK et al (2004) Prevalence of familial pancreatic cancer in Germany. Int J Cancer 110(6):902–906 CrossRefPubMed

Berlin J, Catalano P, Thomas J et al (2002) A phase III study of gemcitabine in combination with 5-FU vs gemcitabine alone in patients with advanced pancreatic carcinoma (E2297): an Eastern Cooperative Oncology Group (ECOG) trial. J Clin Oncol 20:3270–3275 CrossRefPubMed

Bronstein YL et al (2004) Detection of small pancreatic tumors with multiphasic helical CT. Am J Roentgenol 182(3):619–623 CrossRef

Brugge WR (2008) The incidental pancreatic cyst on abdominal computerizes tomography imaging: diagnosis and management. Clin Gastroenterol Hepatol 6:140–144 CrossRefPubMed

Brunner TB et al (2000) Preoperative chemoradiation in locally advanced pancreatic carcinoma: a phase II study. Onkologie 23(5):436–442 CrossRefPubMed

Burris HA, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413 PubMed

Carpelan-Holmstrom M et al (2002) CEA, CA 19–9 and CA 72–4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 22(4):2311–2316 PubMed

Chauffert B, Mornex F, Bonnetain F et al (2008) Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol 19(9):1592–1599 CrossRefPubMed

Cleary SP et al (2004) Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg 198(5):722–731 CrossRefPubMed

Coleman RE (1998) Clinical PET in oncology. Clin Positron Imaging 1(1):15–30 CrossRefPubMed

Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. N Engl J Med 364:1817–1825 CrossRefPubMed

Crane C et al (2001) Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Gastrointest Cancer 29(1):9–18 CrossRefPubMed

Ducreux M, Rougier P, Pignon J-P et al (2002) A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 13:1185–1191 CrossRefPubMed

Ekbom A et al (1994) Pancreatitis and pancreatic cancer: a population-based study. J Natl Cancer Inst 86(8):625–627 CrossRefPubMed

England RE, Martin DF (1996) Endoscopic and percutaneous intervention in malignant obstructive jaundice. Cardiovasc Intervent Radiol 19(6):381–387 CrossRefPubMed

Eskelinen MHU (2002) Serological tumor markers in pancreatic cancer. In: Diamandis EPFH, Lilja H, Chan DW, Schwartz MK (Hrsg) Tumor markers-physiology pathobiology, technology, and clinical applications. AACC Press, Washington DC, S 265–269

Everhart J, Wright D (1995) Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis JAMA 273(20):1605–1609 PubMed

Fuchs CS et al (1996) A prospective study of cigarette smoking and the risk of pancreatic cancer. Arch Intern Med 156(19):2255–2260 CrossRefPubMed

Gaa J et al (2001) Diagnosis of pancreas tumors: MRI or multidetector spiral CT? Kongressbd Dtsch Ges Chir Kongr 118:73–77 PubMed

Geer RJ, Brennan MF (1993) Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 165(1):68–72 (discussion 72–73) CrossRefPubMed

Giardiello FM et al (2000) Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119(6):1447–1453 CrossRefPubMed

Gillen S, Schuster T, Meyer zum Buschenfelde C et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. Plos 7 e1000267

Glimelius B, Hoffman K, Sjoden PO et al (1996) Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 7:593–600 CrossRefPubMed

Hahn SA et al (2003) BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95(3):214–221 CrossRefPubMed

Hammel PR et al (2000) Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d‘Etude de la Maladie de von Hippel-Lindau. Gastroenterology 119(4):1087–1095 CrossRefPubMed

Hecht F, Hecht BK (1990) Cancer in ataxia-telangiectasia patients. Cancer Genet Cytogenet 46(1):9–19 CrossRefPubMed

Hoffman JP et al (1995) A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg 169(1):71–77 (discussion 77–78) CrossRefPubMed

Howe GR, Jain M, Miller AB (1990) Dietary factors and risk of pancreatic cancer: results of a Canadian population-based case-control study. Int J Cancer 45(4):604–608 CrossRefPubMed

Howe GR et al (1991) Cigarette smoking and cancer of the pancreas: evidence from a population-based case-control study in Toronto, Canada. Int J Cancer 47(3):323–328 CrossRefPubMed

Hruban RH et al (1993) K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 143(2):545–554 PubMedCentralPubMed

Hruban RH et al (2004) An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 28(8):977–987 CrossRefPubMed

Huang QJ et al (2002) Spiral multi-phase CT in evaluating resectability of pancreatic carcinoma. Hepatobiliary Pancreat Dis Int 1(4):614–619 PubMed

Hunt GC, Faigel DO (2002) Assessment of EUS for diagnosing, staging, and determining resectability of pancreatic cancer: a review. Gastrointest Endosc 55(2):232–237 CrossRefPubMed

Jessup JM et al (1993) Neoadjuvant therapy for unresectable pancreatic adenocarcinoma. Arch Surg 128(5):559–564 CrossRefPubMed

Jiang JT et al (2004) Serum level of TSGF, CA242 and CA19–9 in pancreatic cancer. World J Gastroenterol 10(11):1675–1677 PubMed

Kalser MH, Ellenberg SS (1985) Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120(8):899–903 CrossRefPubMed

Karlson BM et al (1999) Abdominal US for diagnosis of pancreatic tumor: prospective cohort analysis. Radiology 213(1):107–111 CrossRefPubMed

Kleeff J, Reiser C et al (2007) Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg 245(4):566–572 PubMedCentralCrossRefPubMed

Klinkenbijl JH et al (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230(6):776–782 (discussion 782–784) PubMedCentralCrossRefPubMed

Kornek GV et al (2000) Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin. Br J Cancer 82(1):98–103 PubMedCentralCrossRefPubMed

La Vecchia C et al (1990) Medical history, diet and pancreatic cancer. Oncology 47(6):463–466 CrossRefPubMed

Laurent-Puig P et al (1995) Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases. Gut 36(3):455–458 PubMedCentralCrossRefPubMed

Lemke AJ et al (2004) Retrospective digital image fusion of multidetector CT and 18 F-FDG PET: clinical value in pancreatic lesions – a prospective study with 104 patients. J Nucl Med 45(8):1279–1286 PubMed

Li CP et al (2003) Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 57(1):98–104 CrossRefPubMed

Loehrer PJ, Feng Y, Cardenes H et al (2011) Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 29:4105–4112 PubMedCentralCrossRefPubMed

Lopez Hanninen E et al (2002) Prospective evaluation of pancreatic tumors: accuracy of MR imaging with MR cholangiopancreatography and MR angiography. Radiology 224(1):34–41 CrossRefPubMed

Louhimo J et al (2004) Serum HCG beta and CA 72–4 are stronger prognostic factors than CEA, CA 19–9 and CA 242 in pancreatic cancer. Oncology 66(2):126–131 CrossRefPubMed

Lowenfels AB et al (1993) Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 328(20):1433–1437 CrossRefPubMed

Lynch HT, Fusaro RM (1991) Pancreatic cancer and the familial atypical multiple mole melanoma (FAMMM) syndrome. Pancreas 6(2):127–131 CrossRefPubMed

Maringhini A et al (1993) Clinical presentation and ultrasonography in the diagnosis of pancreatic cancer. Pancreas 8(2):146–150 CrossRefPubMed

Meyers MO et al (2004) Is reporting of recurrence data important in pancreatic cancer? Ann Surg Oncol 11(3):304–309 CrossRefPubMed

Michaud DS et al (2003) Dietary meat, dairy products, fat, and cholesterol and pancreatic cancer risk in a prospective study. Am J Epidemiol 157(12):1115–1125 CrossRefPubMed

Millikan KW et al (1999) Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg 65(7):618–623 (discussion 623–624) PubMed

Mittal A et al (2004) Matched study of three methods for palliation of malignant pyloroduodenal obstruction. Br J Surg 91(2):205–209 CrossRefPubMed

Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25(15):1960–1966 CrossRefPubMed

Mulcahy HE et al (1998) A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res 4(2):271–275 PubMed

Neoptolemos JP, Stocken DD, Friess H et al (2004) A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350:1200–1210 CrossRefPubMed

Neoptolemos JP, Stocken DD, Bassi C et al (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304(10):1073–1081 CrossRefPubMed

Niedergethmann M, Grützmann R et al (2008) Outcome of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas (IPMN): a 10-year experience. World J Surg 32(10):2253–2260 CrossRefPubMed

Norell SE et al (1986) Diet and pancreatic cancer: a case-control study. Am J Epidemiol 124(6):894–902 PubMed

Oettle H, Post S, Neuhaus P (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer a randomized controlled trial. JAMA 297:267–277 CrossRefPubMed

Ojajarvi IA et al (2000) Occupational exposures and pancreatic cancer: a meta-analysis. Occup Environ Med 57(5):316–324 PubMedCentralCrossRefPubMed

Ozkan H, Kaya M, Cengiz A (2003) Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer. Hepatogastroenterology 50(53):1669–1674 PubMed

Palesty JA, Dudrick SJ (2003) What we have learned about cachexia in gastrointestinal cancer. Dig Dis 21(3):198–213 CrossRefPubMed

Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RC (1994) Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 81:882–885 CrossRefPubMed

Pederzoli P (1998) Phase 3 Trial of SMS 201–995 pa LAR (SMS pa LAR) vs placebo in unresectable stage II, III and IV pancreatic cancer. In: ASCO Annual Meeting

Pedrazzoli S, DiCarlo V et al (1998) Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 228(4):508–517 PubMedCentralCrossRefPubMed

Phillips AR et al (2002) Ethnic disparity of pancreatic cancer in New Zealand. Int J Gastrointest Cancer 31(1–3):137–145 CrossRefPubMed

Pisters PW et al (2001) Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients. Ann Surg 234(1):47–55 PubMedCentralCrossRefPubMed

Povoski SP et al (1999) Preoperative biliary drainage: impact on intraoperative bile cultures and infectious morbidity and mortality after pancreaticoduodenectomy. J Gastrointest Surg 3(5):496–505 CrossRefPubMed

Prott FJ et al (1997) Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: results of a feasibility study. Br J Cancer 75(4):597–601 PubMedCentralCrossRefPubMed

Ren YX et al (2004) Detection of point mutation in K-ras oncogene at codon 12 in pancreatic diseases. World J Gastroenterol 10(6):881–884 PubMed

Reni M, Panucci MG, Passoni P et al (2004) Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial. Cancer Invest 22:688–696 CrossRefPubMed

Rich T et al (2004) Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98–12. Am J Clin Oncol 27(1):51–56 CrossRefPubMed

Richards DA, Kindler HL, Oettle H et al (2004) A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas. Proc Am Soc Clin Oncol 23:A4.007

Ries LA et al (2000) The annual report to the nation on the status of cancer, 1973–1997, with a special section on colorectal cancer. Cancer 88(10):2398–2424 CrossRefPubMed

Risch HA (2003) Etiology of pancreatic cancer, with a hypothesis concerning the role of N-nitroso compounds and excess gastric acidity. J Natl Cancer Inst 95(13):948–960 CrossRefPubMed

Sakorafas GH, Smyrniotis V, Reid-Lombardo KM, Sarr MG (2011) Primary pancreatic cystic neoplasms revisited: Part II Mucinous cystic neoplasms. Surg Oncol 20(2):e93–101 CrossRefPubMed

Santo E (2004) Pancreatic cancer imaging: which method? Jop 5(4):253–257 PubMed

Schima W et al (2002) Diagnosis and staging of pancreatic cancer: comparison of mangafodipir trisodium-enhanced MR imaging and contrast-enhanced helical hydro-CT. Am J Roentgenol 179(3):717–724 CrossRef

Seufferlein T, Bachet LB, Van Cutsem E, Rougier P (2012) Pancreatic adenocarcinoma: ESMO–ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 23(Suppl 7):vi33–vi40 CrossRef

Shinchi H et al (2002) Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 53(1):146–150 CrossRefPubMed

Silverman DT et al (1994) Cigarette smoking and pancreas cancer: a case-control study based on direct interviews. J Natl Cancer Inst 86(20):1510–1516 CrossRefPubMed

Slesak B et al (2004) TPS and CA 19-9 measurements in the follow-up of patients with pancreatic cancer and chronic pancreatitis. Int J Biol Markers 19(2):115–119 PubMed

Snady H et al (2000) Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer 89(2):314–327 CrossRefPubMed

Sohn TA et al (2000) Do preoperative biliary stents increase postpancreaticoduodenectomy complications? J Gastrointest Surg 4(3):258–267 (discussion 267–268) CrossRefPubMed

Swift M, Chase CL, Morrell D (1990) Cancer predisposition of ataxia-telangiectasia heterozygotes. Cancer Genet Cytogenet 46(1):21–27 CrossRefPubMed

Varghese JC et al (1999) Role of MR cholangiopancreatography in patients with failed or inadequate ERCP. Am J Roentgenol 173(6):1527–1533 CrossRef

Vyas S, Markar S, Ezzat TM, Ajit A (2011) Cystic lesions of the pancreas: current trends in approach and management. Postgrad Med J 87:207–214 CrossRefPubMed

Werner JB, Bartosch-Härlid A, Andersson R (2011) Cystic pancreatic lesions: Current evidence for diagnosis and treatment. Scan J Gastroenterol 46(7–8):773–788 CrossRef

Wilkowski R et al (2004) Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic carcinoma. Int J Radiat Oncol Biol Phys 58(3):768–772 CrossRefPubMed

Titel

Pankreastumoren

Buch

Viszeralmedizin

Print ISBN: 978-3-642-14300-7

Electronic ISBN: 978-3-642-14301-4

https://doi.org/10.1007/978-3-642-14301-4

DOI

https://doi.org/10.1007/978-3-642-14301-4_38

Autoren:

Prof. Dr. med. Marcus Bahra
Prof. Dr. med. Florian Lordick
Professor Dr. med. Manfred P. Lutz
Prof. Dr. med. Matthias Glanemann
Prof. Dr. med. Peter Neuhaus

Verlag

Springer Berlin Heidelberg

Sequenznummer

Kapitelnummer

Neu im Fachgebiet Innere Medizin

01.03.2021 | Thorakale und kardiale Radiologie | Nachrichten

Newsletter bestellen

Bildnachweise

Mail Icon II

Springer Medizin

38. Pankreastumoren

Zusammenfassung

Autoren

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

b.Flat Gastrointestinale Chirurgie

b.Flat Viszeral- und Allgemeinchirurgie 360°

Neu im Fachgebiet Innere Medizin

CT-Schema zur Emphysemprognose von Rauchern

So gefährlich sind schwere COVID-19-Verläufe in der Schwangerschaft!

EKG-Pflaster deckt asymptomatisches Vorhofflimmern auf

Verdächtiger Mammografie-Befund? Covid-19-Impfung!

Newsletter